Journal article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
- Abstract:
-
Objective To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239). Methods Patients were stratified by cDMARD use (concomitant cDMARDs use (including methotrexate) or none (past or naïve use)) and randomly assigned to treatment groups (ixekizumab 80 mg every 4 ... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 340.0KB, Terms of use)
-
- Publisher copy:
- 10.1136/rmdopen-2017-000567
Authors
Funding
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- RMD Open More from this journal
- Volume:
- 3
- Issue:
- 2
- Article number:
- e000567
- Publication date:
- 2017-12-22
- Acceptance date:
- 2017-11-05
- DOI:
- ISSN:
-
2056-5933
- Pmid:
-
29299340
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:820315
- UUID:
-
uuid:84bbc719-19b3-4c8b-97bf-2fcf07d7a623
- Local pid:
-
pubs:820315
- Source identifiers:
-
820315
- Deposit date:
-
2018-06-04
Terms of use
- Copyright holder:
- Coates et al
- Copyright date:
- 2017
- Notes:
- This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record